摘要
目的:研究万古霉素联合亚胺培南西司他丁钠或美罗培南抗感染治疗的急性肾损伤发生率的差异,为临床决策提供参考。方法:采用回顾性分析方法,选择2020年1月至2022年12月期间,在孝感市中心医院住院治疗且使用过亚胺培南西司他丁钠联合万古霉素或美罗培南联合万古霉素的患者作为研究对象,联合用药治疗时间最少为72 h。主要研究终点是急性肾损伤的发生率,次要研究终点是发生急性肾损伤的危险因素。结果:共计208名患者纳入分析,其中亚胺培南西司他丁钠联合万古霉素组82例,美罗培南联合万古霉素组126例。亚胺培南西司他丁钠组患者急性肾损伤发生率为8.54%,美罗培南组患者急性肾损伤发生率为20.63%,两组患者急性肾损伤发生率具有统计学意义(P=0.032)。次要终点显示伴有糖尿病是发生急性肾损伤的危险因素。结论:与美罗培南联合万古霉素使用相比,亚胺培南西司他丁钠联合万古霉素抗感染治疗时急性肾损伤发生率较低。
OBJECTIVE To evaluate the difference in the incidence of acute kidney injury(AKI)in anti-infection treatment with vancomycin combined with imipenem/cilastatin sodium or meropenem,providing reference for clinical decision-making.METHODS A retrospective analysis method was adopted,selecting patients hospitalized in Xiaogan Central Hospital from January 2020 to December 2022 who had used imipenem/cilastatin sodium combined with vancomycin or meropenem combined with vancomycin.The minimum duration of combination drug treatment was 72 hours.The primary research endpoint was the incidence of AKI,and the secondary endpoint was risk factors for AKI.RESULTS A total of 208 patients were included in the analysis,with 82 cases in the imipenem/cilastatin sodium and vancomycin group,and 126 cases in the Meropenem and Vancomycin group.The incidence of AKI in the imipenem/cilastatin sodium group was 8.54%,and in the meropenem group was 20.63%,the incidence of AKI between the two groups was statistically significant(P=0.032).The secondary endpoint showed that diabetes was a risk factor for AKI.CONCLUSION Compared with the use of meropenem combined with vancomycin,the incidence of AKI during anti-infection treatment with imipenem/cilastatin sodium combined with vancomycin is lower.
作者
闻超
刘锋
王敏
WEN Chao;LIU Feng;WANG Min(Pharmacy Department,Xiaogan Central Hospital,Hubei Xiaogan 432000,China;Department of General Practice,Xiaogan Central Hospital,Hubei Xiaogan 432000,China;Operating Room of Xiaogan Maternal and Child Health Care Hospital,Hubei Xiaogan 432000,China)
出处
《中国医院药学杂志》
CAS
北大核心
2024年第4期447-450,共4页
Chinese Journal of Hospital Pharmacy
基金
孝感市自然科学基金项目(编号:XGKJ2021010021)。
